# A Pilot Trial of Manlikang in Reducing Salt Intake and Blood Pressure Among Patients With Hypertension

> **NCT03226327** · NA · COMPLETED · sponsor: **Peking University** · enrollment: 43 (actual)

## Conditions studied

- Hypertension
- Hypertension With Abnormal Renal Function

## Interventions

- **DIETARY_SUPPLEMENT:** formula salt with very low sodium (Brand name: Manlikang)

## Key facts

- **NCT ID:** NCT03226327
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2018-07-30
- **Final completion:** 2018-07-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226327, "A Pilot Trial of Manlikang in Reducing Salt Intake and Blood Pressure Among Patients With Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03226327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*